Abstract
Background: Psoriasis is a chronic immune-mediated inflammatory skin disorder that is estimated to affect 2-3% of the general population. The IL-23/IL-17 axis is currently considered to be crucial in the pathogenesis of psoriasis.
Methods: Biologics licensed for psoriasis include the TNFα inhibitors (infliximab, adalimumab, etanercept), the interleukin (IL)-12/23 monoclonal antibody (ustekinumab), and IL-17 inhibitor (secukinumab, ixekizumab).
Results: In this section, we analyse the role of IL-12, IL-23, and IL-17 in psoriasis and evaluated the efficacy and safety of biologic therapies targeting this cytokine.
Conclusion: Dosing regimens, administration modality, and pharmacodynamics profiles of currently available anti-IL-12/IL-23 and IL-17 inhibitors are also examined.
Keywords: Ustekinumab, secukinumab, brodalumab, ixekizumab, efficacy, safety.
Current Pharmaceutical Biotechnology
Title:Biologic Therapy in Psoriasis (Part II): Efficacy and Safety of New Treatment Targeting IL23/IL-17 Pathways
Volume: 18 Issue: 12
Author(s): Elisa Molinelli*, Anna Campanati, Valerio Brisigotti and Annamaria Offidani
Affiliation:
- Dermatology Unit Department of Clinical and Molecular Sciences, Polytechnic Marche University, Ancona,Italy
Keywords: Ustekinumab, secukinumab, brodalumab, ixekizumab, efficacy, safety.
Abstract: Background: Psoriasis is a chronic immune-mediated inflammatory skin disorder that is estimated to affect 2-3% of the general population. The IL-23/IL-17 axis is currently considered to be crucial in the pathogenesis of psoriasis.
Methods: Biologics licensed for psoriasis include the TNFα inhibitors (infliximab, adalimumab, etanercept), the interleukin (IL)-12/23 monoclonal antibody (ustekinumab), and IL-17 inhibitor (secukinumab, ixekizumab).
Results: In this section, we analyse the role of IL-12, IL-23, and IL-17 in psoriasis and evaluated the efficacy and safety of biologic therapies targeting this cytokine.
Conclusion: Dosing regimens, administration modality, and pharmacodynamics profiles of currently available anti-IL-12/IL-23 and IL-17 inhibitors are also examined.
Export Options
About this article
Cite this article as:
Molinelli Elisa*, Campanati Anna, Brisigotti Valerio and Offidani Annamaria, Biologic Therapy in Psoriasis (Part II): Efficacy and Safety of New Treatment Targeting IL23/IL-17 Pathways, Current Pharmaceutical Biotechnology 2017; 18 (12) . https://dx.doi.org/10.2174/1389201019666180103140643
DOI https://dx.doi.org/10.2174/1389201019666180103140643 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
Call for Papers in Thematic Issues
Artificial Intelligence in Bioinformatics
Bioinformatics is an interdisciplinary field that analyzes and explores biological data. This field combines biology and information system. Artificial Intelligence (AI) has attracted great attention as it tries to replicate human intelligence. It has become common technology for analyzing and solving complex data and problems and encompasses sub-fields of machine ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Inducers of Heme Oxygenase-1
Current Pharmaceutical Design The Pathobiology of Osteoarthritis and the Rationale for Using the Chondroitin Sulfate for its Treatment
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Prothrombotic Potential of NSAID in Ischemic Heart Diesase
Mini-Reviews in Medicinal Chemistry Class- and Molecule-specific Differential Effects of Angiotensin II Type 1 Receptor Blockers
Current Pharmaceutical Design Neurotrophic Factors in Combination: A Possible new Therapeutic Strategy to Influence Pathophysiology of Spinal Cord Injury and Repair Mechanisms
Current Pharmaceutical Design Proteases and Their Role in Chronic Inflammatory Lung Diseases
Current Drug Targets Mast Cells in Tissue Healing: From Skin to the Gastrointestinal Tract
Current Pharmaceutical Design EDITORIAL: Recent Advances in Anti-biofilm Strategies
Current Topics in Medicinal Chemistry Invasive Aspergillosis: Focus on New Approaches and New Therapeutic Agents
Current Medicinal Chemistry - Anti-Infective Agents From Endodontic Therapy to Regenerative Endodontics: New Wine in Old Bottles
Current Stem Cell Research & Therapy Antiviral Activity of Jodantipyrin – An Anti-Inflammatory Oral Therapeutic with Interferon-Inducing Properties
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry New Target Antigens for Cancer Immunoprevention
Current Cancer Drug Targets Pregnane X Receptor and its Potential Role in Drug Resistance in Cancer Treatment
Recent Patents on Anti-Cancer Drug Discovery Epidemiology and Pathophysiology of Chronic Cough
Current Respiratory Medicine Reviews Kinase CK2 Inhibition: An Update
Current Medicinal Chemistry Healing Effects of Curcumin Nanoparticles in Deep Tissue Injury Mouse Model
Current Drug Delivery Novel Therapeutic Approaches Targeting Matrix Metalloproteinases in Cardiovascular Disease
Current Topics in Medicinal Chemistry Establishment of Novel Cells Stably Secreting Various Human IL-18 Recombinant Proteins
Current Pharmaceutical Biotechnology Targeting the Human Thioredoxin System by Diverse Strategies to Treat Cancer and Other Pathologies
Recent Patents on DNA & Gene Sequences Patenting Networking and Knowledge Translation in Liposomes for Cancer Therapy
Recent Patents on Nanomedicine